---
title: "康方生物科技(开曼)有限公司 (09926.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/09926.HK.md"
symbol: "09926.HK"
name: "康方生物科技(开曼)有限公司"
industry: "生物技术"
---

# 康方生物科技(开曼)有限公司 (09926.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 港股市场 |
| Website | [www.akesobio.com](https://www.akesobio.com) |

## Company Profile

康方生物科技 (开曼) 有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括用于肿瘤领域的开坦尼 (卡度尼利，PD-1/CTLA-4)、依达方 (依沃西，PD-1/VEGF)、莱法利 (AK117,CD47)、普络西 (AK109,VEGFR-2)、安尼可 (派安普利，PD-1)、科泰莱 (塔戈利单抗，PD-L1) 和用于代谢及自免领域的伊喜宁 (伊努西单抗，PCSK9)、爱达罗 (依若奇单抗，IL-12/IL-23)、古莫奇单抗 (AK111,IL-17)。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 13 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 34.17% |  |
| Net Profit YoY | -15.22% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 13.73 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 96.91B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.72B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -14.51% | E |
| Profit Margin | -33.70% | E |
| Gross Margin | 78.28% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 34.17% | A |
| Net Profit YoY | -15.22% | D |
| Total Assets YoY | 29.41% | A |
| Net Assets YoY | 25.93% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -296.78% | D |
| OCF YoY | 34.17% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.21 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 52.16% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 康方生物科技(开曼)有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-14.51%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-33.70%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "78.28%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "34.17%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-15.22%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "29.41%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "25.93%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-296.78%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "34.17%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "52.16%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 百济神州 (HK.6160) | C | A | B | C | A | B |
| 02 | 信达生物 (HK.1801) | B | A | C | B | A | B |
| 03 | 三生制药 (HK.1530) | A | B | C | A | C | B |
| 04 | 百奥赛图-B (HK.2315) | A | A | C | D | B | B |
| 05 | 和铂医药-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -108.33 | 67/70 | - | - | - |
| PB | 14.24 | 48/70 | 17.14 | 14.70 | 10.78 |
| PS (TTM) | 36.50 | 40/70 | 45.34 | 38.14 | 32.80 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-16T16:00:00.000Z

Total Analysts: **24**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 17 | 71% |
| Overweight | 4 | 17% |
| Hold | 3 | 13% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 109.10 |
| Highest Target | 233.00 |
| Lowest Target | 117.13 |

## References

- [Company Overview](https://longbridge.com/en/quote/09926.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/09926.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/09926.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.